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Abstract (245 words) 
  Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib 
and erlotinib, are effective for non-small cell lung cancer with activating EGFR 
mutations. However, even in patients with an initial dramatic response to such a drug, 
acquired resistance develops after 6–12 months. A secondary mutation of T790M in 
EGFR and amplification of the MET gene account for this resistance; however, the 
mechanism(s) of approximately 30% of acquired resistance cases remain unknown. We 
established an erlotinib-resistant lung cancer cell line named PC-9/ER3 that harbors an 
EGFR mutation after continuously exposing PC-9 cells to erlotinib. PC-9/ER3 cells 
were 136-fold more resistant to erlotinib than the parental cells. Although the PC-9/ER3 
cells did not carry the T790M mutation or MET amplification and had similar levels of 
phosphorylated (p) STAT3, pJAK2 increased in the resistant cells. Three to 12 hours of 
exposure to erlotinib in both cell lines did not affect pJAK2 expression, but did result in 
increased pSTAT3 expression. pAkt in PC-9/ER3 cells was less suppressed than in PC-9 
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cells, although pEGFR and pMAPK were markedly suppressed in both cell lines. The 
combined treatment of erlotinib plus a JAK2 inhibitor (JSI-124) suppressed pAkt in 
PC-9/ER3 cells. Similarly, the combination of erlotinib plus JSI-124 or siRNA against 
JAK2 restored sensitivity to erlotinib in PC-9/ER3 cells. The combination of erlotinib 
plus JSI-124 was also effective for reducing PC-9/ER3 tumors in a murine xenograft 
model. Our results suggest that the activation of JAK2 partially accounts for acquired 
erlotinib resistance. 
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Introduction 
 
  Lung cancer, the leading cause of cancer-related death in the United States, accounted 
for 29% of all male cancer deaths and 26% of all female cancer deaths in 20111. The 
overall 5-year survival rate of patients with metastatic disease remains less than 15% 2. 
However, somatic mutations were discovered to exist in the epidermal growth factor 
receptor (EGFR) tyrosine kinase in a subset of patients with non-small cell lung cancer 
(NSCLC) 3-5. Remarkably, these mutations strongly sensitize the cancer cells to the 
growth suppressive effects of the EGFR tyrosine kinase inhibitors (TKIs), gefitinib and 
erlotinib, leading to clinical responses 3, 4, 6, 7. However, the majority of NSCLCs 
initially sensitive to gefitinib or erlotinib become resistant to these agents within 1 year 
8
. Once EGFR mutant lung cancer develops into progressive disease during treatment 
with EGFR-TKI, no optimal therapy has yet been established. Several possible 
mechanisms for the acquired resistance have been identified, the most common being 
the development of an EGFR T790M gatekeeper mutation in around 50% of cases 9. 
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Other mechanisms of acquired resistance include bypass signaling, such as MET 
amplification 10, PTEN loss 11, and hepatocyte growth factor (HGF) overexpression 12. 
Approximately 30% of cases remain for which the mechanism of acquired resistance is 
presently unknown 9. Clinical trials testing the tolerance for changing treatment 
regimens to include irreversible TKI, such as BIBW2992, to prevent acquired resistance 
via T790M or combining EGFR-TKI with a MET inhibitor to prevent acquired 
resistance via amplification of MET, have been performed 13, 14. 
  Phosphoinositide 3 kinase (PI3K)/Akt, Ras/mitogen-activated protein kinase 
(MAPK), and signal transducer and activator of transcription 3 (STAT3) are three major 
downstream pathways activated by EGFR phosphorylation 15. STAT3 has been reported 
to be a critical mediator of the oncogenic effects of EGFR mutations 16. Non-receptor 
tyrosine kinases, such as Src and Janus kinase 2 (JAK2), also phosphorylate STAT3 17. 
In this study, we isolated one cell line (PC-9/ER3) from five erlotinib-resistant clones 
generated in vitro from parental PC-9 cells that harbored the activating EGFR mutation 
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by chronically exposing the cell line to erlotinib. As PC-9/ER3 cells harbored neither 
the T790M mutation nor MET gene amplification, we investigated EGFR signaling 
abnormalities, including those involving JAK2, STAT3, Akt, and MAPK, in these cells.  
 
Page 7 of 49
CAS Editorial office (Email: cancerscience@wiley.com)
Cancer Science
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review
7 
 
Materials and Methods 
 
Establishment of an erlotinib-resistant cell line 
  The human NSCLC cell line PC-9 was derived from an untreated Japanese patient 
with pulmonary adenocarcinoma that carried an in-frame deletion in EGFR exon 19 (del 
E746-A750) and was highly sensitive to EGFR-TKI 18. PC-9 cells were purchased from 
Immuno-Biological Laboratories and were cultured at 37°C with 5% CO2 in 
RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum. To 
establish an erlotinib-resistant subline, the cells were treated with gradually increasing 
concentrations of erlotinib, starting at 0.02 µmol/L, which was near the 50% inhibitory 
concentration (IC50) of the drug in PC-9 cells (Fig. 1A). After 12 weeks, the cells were 
able to grow in 5 µmol/L erlotinib. Then, we performed single-cell cloning by limiting 
dilution and obtained five erlotinib-resistant cell lines. 
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Sensitivity test 
  Growth inhibition was measured by a modified 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 19. Briefly, 
the cells were plated onto 96-well plates at a density of about 3 × 103 cells per well and 
exposed to erlotinib for 96 hours. Each assay was done in quadruplicate and the mean ± 
standard deviation of the IC50 was calculated. Among the five erlotinib-resistant clones, 
the PC-9/ER3 cell line did not harbor the T790M mutation, and its resistance was stable 
for at least 20 weeks. Thus, we used PC-9/ER3 cells to investigate acquired resistance to 
erlotinib. 
 
Reagents and antibodies 
  Erlotinib was purchased from Chemie Tek. JSI-124 (cucurbitacin I) 17, a selective 
JAK2 inhibitor, and stattic 20, an inhibitor of STAT3 activation, were acquired from 
Calbiochem. LY294002 21, a potent inhibitor of PI3K, was obtained from Cell Signaling 
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Technology, Inc. Rabbit antisera against EGFR, pEGFR (pY1068), pSTAT3 (pY705), 
extracellular signal-regulated kinase 1/2 (ERK1/2), pERK (pT202/pY204), pAkt 
(pSer473), total Akt, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were 
purchased from Cell Signaling Technology. Polyclonal anti-pJAK2 (pY1007/1008) 
antibody was obtained from Millipore Corporation. Other polyclonal antibodies against 
JAK2, STAT3, survivin, and c-MYC were purchased from Santa Cruz Biotechnology. 
 
Sequencing of the EGFR gene 
  To determine the EGFR sequence, DNA was extracted from each cell line using a 
QIAamp DNA Mini Kit (Qiagen), and the exons encoding the intracellular domain 
(exons 18–22) were amplified by polymerase chain reaction (PCR). Primer sequences 
and amplification conditions were as described previously 5. PCR products were 
processed with a BigDye Terminator Cycle sequencing kit (Applied Biosystems) and 
analyzed in both the sense and antisense directions for the presence of mutations on an 
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ABI 3100 sequencer (Applied Biosystems). 
 
Quantitative PCR 
  Quantitative PCR was performed on a GeneAmp 5700 (Applied Biosystems). The 
copy number ratio of MET to GAPDH, a housekeeping gene, was calculated using a 
genomic DNA sample. The sequences of the Taqman probe and primers for MET and 
GAPDH were as follows: human MET, 
5′-FAM-TGCCTGCGAAGTGAAGGGTCTCCG-TAMRA-3′ (Taqman probe), 
5′-CCAATTTCTGACCGAGGGAATC-3′ (forward primer), and 5′-GTCCTACCAT‐
ACATGAAACATGGA-3′ (reverse primer); human GAPDH, 
5′-FAM-TCAAGGTGGGGAGGGAGGTAGAGGGG-TAMRA-3′ (Taqman probe), 
5′-GGCTCCCACCTTTCTCATCC-3′ (forward primer), and 
5′-GATGTGGGGAGTACGCTGC-3′ (reverse primer).  
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Western blot analysis 
  Cells were lysed with radioimmunoprecipitation assay buffer [1% Triton X-100, 0.1% 
sodium dodecyl sulfate (SDS), 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 
1 mM EGTA, 10 mM β-glycerol-phosphate, 10 mM NaF, and 1 mM Na-orthovanadate] 
containing the respective protease inhibitor tablet (Roche). Whole cell lysates were 
separated with SDS–polyacrylamide gel electrophoresis (PAGE) and then transferred to 
a membrane and detected by antibodies using ECL Plus Western blot detection reagents 
(GE Healthcare Biosciences). Each protein was incubated with an appropriate primary 
antibody and detected by horseradish peroxidase (HRP)-mediated chemiluminescence 
(ECL Plus).  
 
Xenograft model 
  Female BALB/c nu/nu mice at 7 weeks of age were purchased from Japan Charles 
River Co. All mice were provided with sterilized food and water and housed in a barrier 
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facility under a 12-h light/dark cycle. Cells (2 × 106) were injected subcutaneously (s.c.) 
into the backs of the mice. At 1 week after injection, the mice were randomly assigned 
to one of four groups (five to six mice per group) that received vehicle, 25 mg/kg/day 
erlotinib, 1 mg/kg/day JSI-124, or 25 mg/kg/day erlotinib plus 1 mg/kg/day JSI-124. 
Vehicle and erlotinib were administered once a day, five times a week by gavage. 
JSI-124 (1 mg/kg) was administered once a day, five times a week intraperitoneally 
(i.p.). Tumor volume (width2 × length/2) was determined periodically. 
  All experiments involving animals were performed under the auspices of the 
Institutional Animal Care and Research Advisory Committee of the Department of 
Animal Resources, Okayama University Advanced Science Research. 
 
siRNA gene knockdown 
  MISSION predesigned small interfering (si)RNAs (Sigma) targeting STAT3 and 
JAK2 sequences were 5′-GGAUAACGUCAUUAGCAGA[dT][dT]-3′ and 5′- 
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UCUGCUAAUGACGUUAUCC[dT][dT]-3′ and 
5′-GAUAGGUGCCCUAGGGUUU[dT][dT]-3′ and 
5′-AAACCCUAGGGCACCUAUC[dT][dT]-3′, respectively. MISSION siRNA 
Universal Negative Control (Sigma) was used as a non-targeting control for siRNA 
experiments. PC-9 and PC-9/ER3 cells were transiently transfected with the 
combination of two siRNA duplexes (5 nM STAT3-specific siRNA and 30 nM 
JAK2-specific siRNA) using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocol. Assays for silencing were performed on confluent monolayers 
24 or 36 hours after transfection. Protein expression after siRNA knockdown was 
evaluated by Western blot analysis. Proliferation of PC-9/ER3 and PC-9 cells, in which 
STAT3 or JAK2 was knocked down by siRNA, was measured using the MTT assay as 
described above. 
 
Statistical analysis 
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The differences between the groups were compared using Student’s t-test. P < 0.05 was 
considered statistically significant. All data were analyzed using Microsoft Office Excel 
2007 (Microsoft Japan Corporation, Tokyo). 
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Results 
 
PC-9/ER3 cells were established after continuous exposure of PC-9 cells to 
erlotinib 
  By microscopic observation, PC-9/ER3 cells showed the same morphology as the 
parental PC-9 cells (Fig. 1B). The rate of proliferation of PC-9/ER3 cells was similar to 
that of PC-9 cells, with doubling times of 13.3 and 17.5 hours (P = 0.43), respectively 
(Fig. 1C). The parental PC-9 cells could not proliferate in the presence of 1 µmol/L 
erlotinib, whereas PC-9/ER3 cells continued to grow under the same condition (Fig. 1B). 
The IC50 values of erlotinib in the PC-9 and the PC-9/ER3 cells were 0.0089 ± 0.0001 
and 1.21 ± 0.11 µmol/L, respectively. PC-9/ER3 cells were 136-fold more resistant to 
erlotinib than the parental PC-9 cells. The resistance was stable for at least 20 weeks 
without exposure to erlotinib (Fig. 1D). The IC50 values for gefitinib were 0.011 ± 0.001 
µmol/L in PC-9 cells and 2.78 ± 0.42 µmol/L in PC-9/ER3 cells, indicating that 
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PC-9/ER3 cells showed cross-resistance to gefitinib that was 252-fold higher than in 
PC-9 cells. Both PC-9/ER4 and PC-9/ER5 cells were also resistant to erlotinib and 
gefitinib (Supplemental Fig. 1). 
 
Mechanism of erlotinib resistance is not due to the T790M point mutation or MET 
gene amplification 
  To examine genetic alterations, including the well-known T790M mutation, we 
conducted direct sequencing of EGFR at exons 18–22. The T790M mutation at exon 20 
was not observed in the PC-9/ER3 cells (Fig. 2A). No other genetic differences in 
EGFR DNA sequences 22 between PC-9 and PC-9/ER3 cells were detected. Next, we 
used a more sensitive assay for the EGFR T790M mutation: the peptide nucleic 
acid-locked nucleic acid (PNA-LNA) PCR clamp-based detection test (Mitsubishi 
Chemical Medience Corp.), which can detect mutations present in 0.1% to 1% of 
samples 23, 24. This method also failed to detect the T790M mutation in PC-9/ER3 cells, 
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confirming the results of direct sequencing. In addition, the PCR-Invader method (Bio 
Medical Laboratories), which was more sensitive than the direct sequencing and was as 
sensitive as PNA-LNA PCR clamp-based detection test 25, also failed to detect T790M 
in the other resistant cell lines (PC-9/ER1, 2, 3, 4 and 5). 
  The second most common cause of acquired resistance of NSCLC to EGFR-TKIs in 
vitro and in vivo involves the amplification of MET 10, 26, 27. We examined differences in 
MET amplification between PC-9 and PC-9/ER1, 2, 3, 4 and 5 cells using a quantitative 
PCR method. No MET gene amplification was detected in PC-9/ER3 cells (Fig. 2B) or 
the other resistant cells (PC-9/ER1, 2, 4 and 5) (Supplemental Fig. 2). In addition, 
PTEN expression was similar in both PC-9 and PC-9/ER3 cell lines (Fig. 2C).  
 
pJAK2 increased in PC-9/ER3 cells 
  PC-9 and PC-9/ER3 cells were treated with erlotinib (0.05 µM) for various lengths of 
time (0–12 hours). pEGFR and pMAPK in both cell lines were markedly suppressed by 
erlotinib. However, pAkt, which is an effector molecule downstream of EGFR, was not 
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inhibited by erlotinib, and pJAK2 increased in PC-9/ER3 more than in the parental 
PC-9 cells (Fig. 3). JAK2 in both PC-9/ER4 and PC-9/ER5 cells was also activated 
(Supplemental Fig. 3). Phosphorylation of STAT3, which is a downstream effector of 
JAK2, increased time-dependently in both PC-9 and PC-9/ER3 cells after treatment 
with erlotinib. Although expression of survivin, the anti-apoptotic gene that is 
downstream of STAT3, did not change during erlotinib treatment, PC-9/ER3 cells had 
more expressions than PC-9 cells as a base line (Fig. 3). 
 
Inhibition of JAK2 rather than STAT3 restores the sensitivity of PC-9/ER3 cells to 
erlotinib 
  We hypothesized that the inhibition of JAK2/STAT3 or PI3K/Akt might restore 
sensitivity to erlotinib in PC-9/ER3 cells. The differences in sensitivity to treatment with 
erlotinib plus or minus JSI-124, LY294002, or stattic were evaluated using the MTT 
assay (Fig. 4A–F). JSI-124, LY294002 and stattic suppressed pJAK2, pAkt and pSTAT3, 
respectively, in both PC-9 and PC-9/ER3 cells (Fig. 5 and Supplemental Fig. 4). Cells 
were treated with the indicated concentration of erlotinib in combination with the 
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approximate IC50 concentration of each drug (0.05 µM JSI-124, 15 µM LY294002, or 5 
µM stattic) for 96 hours. The respective sensitivities of PC-9 and PC-9/ER3 cells to 
JSI-124 alone were quite similar (Fig. 4A). The sensitivity of the PC-9/ER3 cells to 
erlotinib was restored by the combined treatment of erlotinib plus JSI-124 to a level 
comparable to that of PC-9, while the sensitivity of PC-9 cells to erlotinib did not 
increase with the same treatment (Fig. 4B). The sensitivity of PC-9/ER3 cells to 
LY294002 was slightly higher than that of PC-9 cells (Fig. 4C). The erlotinib sensitivity 
of PC-9/ER3 cells was moderately restored upon treatment with erlotinib plus 
LY294002, but that of PC-9 cells was not affected (Fig. 4D). The sensitivity of both cell 
lines to stattic was similar (Fig. 4E). However, the sensitivity of PC-9/ER3 cells to 
erlotinib was nearly unaffected by the presence of static, while the sensitivity of the 
PC-9 cells to erlotinib in the presence of static decreased (Fig. 4F).  
  To confirm the interaction of erlotinib (0.01 µM) with JSI-124 (0.03 µM), LY294002 
(5 µM), or stattic (2 µM), the number of viable cells after drug exposure for 96 hours 
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was counted. As shown in Figure 4G, the growth inhibition ratio after treatment with 
erlotinib plus JSI-124 of PC-9/ER3 cells increased significantly (P < 0.05). That was 
also proved in PC-9/ER5 cells (Supplemental Fig. 5). However, the combination of 
erlotinib with LY294002 or stattic was not effective in the resistant cells.  
  These results suggest that the combination of erlotinib with a JAK2 inhibitor was 
more effective than the combination of erlotinib with a STAT3 inhibitor in PC-9/ER3 
cells. 
 
The combination of erlotinib with JSI-124 suppresses pAkt in PC-9/ER3 cells 
To determine whether the combined effect of erlotinib with JSI-124 correlated with 
changes in MAPK or Akt signaling pathways, cells were treated with erlotinib alone, 
JSI-124 alone, or the combination of both drugs, and the lysates were processed for 
Western blotting with antibodies specific for pJAK2, pSTAT3, pAkt, and pMAPK. 
Figure 5 shows that treatment with erlotinib alone inhibited pMAPK in both cell lines as 
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well as pAkt in PC-9, but not in PC-9/ER3 cells. We used 10 µM of JSI-124, which 
seemed high compared to the results from MTT assays. However, treatment duration of 
the drug was 6 hours in Western blot analysis and 96 hours in MTT assays. The 
concentration of JSI-124 was referred from the report of Blaskovich et al 17. Treatment 
with JSI-124 alone inhibited pJAK2, pSTAT3, and pMAPK in both cell lines as well as 
pAkt in PC-9/ER3 cells, but not in PC-9 cells. As expected, the phosphorylation of Akt 
in PC-9 cells treated with both erlotinib and JSI-124 was similar to that with erlotinib 
alone. However, in PC-9/ER3 cells, JSI-124 moderately suppressed pAkt. Additionally, 
the combination of both drugs suppressed pAkt as much as that detected in PC-9 cells 
treated with erlotinib alone. The combination of si-JAK2 with erlotinib suppressed pAkt 
in PC-9/ER3 cells (Supplemental Fig. 6). 
 
siRNA knockdown of JAK2 also recovers sensitivity to erlotinib in PC-9/ER3 cells 
  We examined whether siRNA knockdown of STAT3 or JAK2 would restore the 
Page 22 of 49
CAS Editorial office (Email: cancerscience@wiley.com)
Cancer Science
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review
22 
 
sensitivity to erlotinib in PC-9/ER3 cells (Fig. 6). Accordingly, gene-specific siRNAs 
were transfected into PC-9 and PC-9/ER3 cells. The mock (control) transfected cells 
received transfection reagents without siRNA. siRNA specific for STAT3 and JAK2 
lowered STAT3 and JAK2 expression, respectively (Fig. 6A and C). Subsequently, we 
evaluated the growth inhibition of each cell line by erlotinib using MTT assays. The 
knockdown of STAT3 did not increase the sensitivity to erlotinib of either cell line (Fig. 
6B). The knockdown of JAK2 did not influence the sensitivity of PC-9 cells to erlotinib, 
but it did restore the sensitivity of PC-9/ER3 cells to erlotinib (Fig. 6D). These results 
suggest that the resistance of PC-9/ER3 cells to erlotinib was not induced by the 
activation of the JAK2/STAT3 pathway, but rather a JAK2-related pathway, such as the 
PI3K/Akt pathway. 
 
The combination of erlotinib with JSI-124 to treat PC-9/ER3 tumors in a xenograft 
model is effective 
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  The antitumor effect of the combination of erlotinib with JSI-124 was examined in 
vivo. PC-9/ER3 xenograft model mice were treated with JSI-124 alone, erlotinib alone, 
erlotinib in combination with JSI-124, or vehicle alone (Fig. 7). JSI-124 alone did not 
inhibit tumor growth. Erlotinib alone did not significantly affect tumor volume. The 
two-drug combination induced significant tumor shrinkage compared with either drug 
alone (P < 0.05). These results showed that the combination of erlotinib and JSI-124 
restored the sensitivity of PC-9/ER3 cells to erlotinib in vivo.  
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Discussion 
 
  Several EGFR-related proteins were evaluated to identify the signal abnormalities of 
erlotinib-resistant PC-9/ER3 cells, which had JAK2 activation without STAT3 
activation. We found that JAK2 phosphorylation followed by the activation of Akt 
partially accounted for acquired erlotinib resistance and that resistance could be 
overcome by treatment with a combination of erlotinib and a JAK2 inhibitor. 
  The STAT family of transcription factors consists of seven proteins in humans 
(STAT1–STAT4, STAT5A, STAT5B, and STAT6) that are encoded by separate genes. 
STAT3 and STAT5 are the STATs most often implicated in human cancer progression 28. 
Activated STAT3 and STAT5 were expressed in about 55% and 33% of NSCLC tumors, 
respectively 29, 30. STAT3 has been the subject of more investigations than STAT5 28. 
Our previous study showed that pSTAT3 was less suppressed compared to EGFR 
despite the administration of gefitinib in our mutant EGFR-transgenic mice. It suggests 
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that signals from other upstream might activate STAT3 even in EGFR-driven lung 
cancer 31. Although we focused on STAT3 in this study, STAT5 should be further 
examined in our future experiment. Aberrant STAT3 activation was shown to be 
required for the survival of human cancer cells by promoting the overexpression of 
genes that encode anti-apoptotic proteins, cell-cycle regulators, and angiogenic factors 
32-34
. STAT activation by cytokines is mediated through JAKs, which include four 
family members, JAK1, JAK2, JAK3, and Tyk2 35. In PC-9/ER3 cells, STAT3 did not 
seem to play a critical role in erlotinib resistance. Activation of Akt was inhibited by 
blocking activation of JAK2 in PC-9/ER3 cells (Fig. 5). Although a direct relationship 
between the JAK2 and Akt pathways remains unclear, our data indicated a connection. 
Vogt and Hart supposed that two branches of oncogenic signal initiated by PI3K 
(Akt-mTOR and BMX-STAT3 pathways) were networked 36. Although it has never 
been proved, Akt from JAK2 axis in EGFR resistance might emerge in the network. 
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  Recent studies in breast cancer, lung cancer, and diffuse large B cell lymphoma cell 
lines have demonstrated a central role for JAK family kinases in mediating IL-6 
signaling in these cells 29, 37, 38. Our study provides a molecular reason for JAK2 
activation and highlights JAK2 as one of several mechanisms of acquired drug 
resistance and a potential target for recovery from resistance. No difference was 
observed in IL-6 protein levels evaluated by enzyme-linked immunosorbent assay 
between PC-9 and PC-9/ER3 cells (data not shown). Lee et al. reported that JAK1 and 
JAK2 activation participates in IL-5-induced upregulation of c-MYC in a human 
hematopoietic progenitor cell line 39. In Bcr-Abl+ chronic myelogenous leukemia cells, 
the activation of JAK2 did not lead to STAT5 activation, which was activated by 
Bcr-Abl 40, 41. One major effect of the activation of JAK2 by the Bcr-Abl oncoprotein is 
increased c-MYC expression, which is required for leukemia induction 40-43. Inhibition 
of JAK2 resulted in decreased pAkt and c-MYC in imatinib-resistant chronic 
myelogenous leukemia cells, and JAK2 was identified as a potentially important 
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therapeutic target for imatinib-resistant chronic myelogenous leukemia 43. MYC is a 
classical oncogene in lung cancer, and its amplification in adenocarcinoma of the lung 
occurs in both late and early stages of lung cancer progression and serves as a 
prognostic molecular marker 44. Thus, we expected that inhibition of JAK2 would result 
in decreased pAkt and c-MYC, which would lead to PC-9/ER3 cell death independently 
of STAT3 suppression. In reality, JAK2-specific siRNA inhibited c-MYC expression, 
and the combination of erlotinib and JSI-124 efficiently suppressed c-MYC expression 
in PC-9/ER3 cells (Supplemental Fig. 7). The relationships among JAK2, Akt, and 
MYC as downstream signals of EGFR in erlotinib-resistant lung cancer cells should be 
pursued further.  
  Our study had some limitations. Only one cell line (PC-9/ER3) was extensively 
investigated. The activation of JAK2 was also considered to be one of the various 
EGFR-TKI-resistant mechanisms in the other resistant line (PC-9/ER5) derived from 
PC-9. However, this mechanism may be applied only to PC-9. We should establish 
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further EGFR-TKI-resistant cell lines derived from other sensitive cell lines such as 
HCC827 and H3255, and need to verify whether activated JAK2 was really related with 
the resistant mechanism. Additionally, the resistant cells were 136-fold more resistant to 
erlotinib than the parental cells, which is not easily translatable to a clinical situation. 
However, such a big difference in sensitivity to erlotinib between the cells may have 
helped us identify a new mechanism of resistance. Patients with NSCLC who 
underwent surgery and had high pJAK2 expression had a significantly worse overall 
survival rate compared with those with low pJAK2 expression 45. Future studies should 
examine pJAK2 expression in EGFR-TKI-resistant clinical samples. 
  Unexpectedly, PC-9/ER3 cells did not carry the T790M mutation, although PC-9 
cells easily developed the T790M mutation after continuous exposure to gefitinib 46 or 
vandetanib 47. Five (12.8%) of 39 erlotinib-resistant tumors in mutated EGFR-driven 
transgenic mice expressed the T790M mutation 48. The reason why PC-9/ER3 cells 
Page 29 of 49
CAS Editorial office (Email: cancerscience@wiley.com)
Cancer Science
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review
29 
 
selectively bypassed JAK2 signaling but did not develop the T790M mutation or MET 
overexpression remains unknown. 
  In conclusion, we were able to show participation of the JAK2 pathway as one of the 
mechanisms of acquired erlotinib resistance and that acquired erlotinib resistance could 
be overcome by suppression of the JAK2 pathway both in vitro and in vivo.  
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Figure Legends 
 
Figure 1. Establishment of an erlotinib-resistant lung cancer cell line. 
A, Overview of the strategy to establish erlotinib-resistant cells from PC-9 cells. B, A 
light microscopic (×100) image of PC-9 and PC-9/ER3 cells. Cells were exposed to 
erlotinib (1 µM) for 72 hours. C, Relative cell numbers of PC-9 and PC-9/ER3 are 
shown in the culture medium for 72 hours. PC-9 and PC-9/ER3 cells were seeded on 
6-cm dishes (4 × 105 per dish) in the absence of erlotinib. Cells were trypsinized and 
counted in triplicate. DT, doubling time. Data are presented as the mean ± standard 
error. D, Cells (3 × 103 per well) were seeded onto 96- ell plates in quadruplicate and 
grown in the absence or presence of the indicated concentration of erlotinib. After 96 
hours, the cells were subjected to MTT assays. PC-9/ER3 cells were maintained in 
culture medium without erlotinib for 5 (5W), 10 (10W), or 20 (20W) weeks.  
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Figure 2. Characterization of PC-9/ER3 cells. 
A, The T790M mutation was not found in PC-9/ER3 cells by direct sequencing. B, MET 
gene copy number was examined by quantitative PCR using genomic DNA extracted 
from PC-9 and PC-9/ER3 cells. MET gene copy number relative to GAPDH was 
measured in three independent experiments. Bars, standard deviation. C, Cells were 
incubated with or without 2 µM erlotinib for 6 hours and subjected to Western blotting. 
pEGFR was suppressed, and PTEN expression was similar in both cell lines. 
 
Figure 3. Protein expression in PC-9 and PC-9/ER3 cells treated with erlotinib for 
various lengths of time. 
pEGFR and pMAPK in both cell lines were markedly suppressed. pAkt was not 
inhibited by erlotinib, and pJAK2 increased in PC-9/ER3 cells more than in the parental 
PC-9 cells. pSTAT3 increased in both PC-9 and PC-9/ER3 cells in a time-dependent 
manner. Although expression of survivin did not change during erlotinib treatment, 
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PC-9/ER3 cells had more expressions than PC-9 cells as a base line. 
 
Figure 4. Comparison of cell growth after treatment with drugs alone or in 
combination. 
A, Cells (3 × 103 per well) were seeded in 96-well plates in quadruplicate and grown in 
the absence or presence of the indicated concentration of JSI-124. After 96 hours, the 
cells were subjected to MTT assays. B, Cells (3 × 103 per well) were seeded in 96-well 
plates in quadruplicate and grown in the absence or presence of the indicated 
concentration of erlotinib with or without 0.05 µM JSI-124. After 96 hours, the cells 
were subjected to MTT assays. C and D, Same as in (A) and (B), respectively, but with 
LY294002. The concentration of LY290442 in (D) was 15 µM. E and F, Same as in (A) 
and (B), respectively, but with stattic. The concentration of stattic in (F) was 5 µM. G, 
Cells were treated with 10 nM erlotinib plus or minus 30 nM JSI-124 (left panel), 5 µM 
LY294002 (center panel), or 2 µM stattic (right panel) for 96 hours. Growth inhibition 
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relative to erlotinib-untreated cells with or without JSI-124, LY294002, or stattic are 
shown. Data are representative of two independent experiments. Bars, standard error.  
 
Figure 5. Protein expression in PC-9 and PC-9/ER3 cells upon treatment with erlotinib 
plus or minus JSI-124. 
Extracts from PC-9 and PC-9/ER3 cell lines, treated with erlotinib (0.01 µM) or JSI-124 
(10 µM) or both for 6 hours, were subjected to Western blotting. Treatment with 
erlotinib alone inhibited pMAPK in both cell lines and pAkt in PC-9, but not PC-9/ER3, 
cells. Treatment with JSI-124 alone inhibited pJAK2, pSTAT3, and pMAPK in both cell 
lines and pAkt in PC-9/ER3, but not in PC-9, cells. pAkt in PC-9 cells treated with both 
erlotinib and JSI-124 was similar to that with erlotinib alone. However, in PC-9/ER3 
cells, JSI-124 moderately suppressed pAkt. The combination of both drugs suppressed 
pAkt as much as that in PC-9 cells treated with erlotinib alone. 
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Figure 6. siRNA knockdown of STAT3 and JAK2. 
A, STAT3 was knocked down in PC-9 and PC-9/ER3 cells by STAT3-specific siRNA. B, 
Cells (3 × 103 per well) were seeded in 96-well plates in quadruplicate and grown with 
the indicated concentration of erlotinib. After 96 hours, the cells were subjected to MTT 
assays. The knockdown of STAT3 did not affect the sensitivity to erlotinib of either cell 
line. C, JAK2-specific siRNA lowered JAK2 expression. D, The knockdown of JAK2 
did not influence the sensitivity of PC-9 cells to erlotinib, but restored the sensitivity of 
PC-9/ER3 cells to erlotinib. 
 
Figure 7. Growth curves of PC-9/ER3 xenograft tumors. 
PC-9/ER3 xenograft model mice were treated with JSI-124 (1 mg/kg/day) alone, 
erlotinib (25 mg/kg/day) alone, erlotinib in combination with JSI-124, or vehicle alone. 
JSI-124 alone did not inhibit tumor growth. Erlotinib alone did not significantly affect 
the tumor volume. The two-drug combination resulted in significant tumor shrinkage 
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compared to either drug alone (P < 0.05). Differences in tumor volume were compared 
using Student's t-test. Bars, standard error. 
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Supporting information 
 
Supplemental Figure 1. IC50 values of erlotinib and gefitinib in PC-9, PC-9/ER3, 4 and 
5 cells determined by MTT assay.  
 
Supplemental Figure 2. MET gene copy number relative to GAPDH in PC-9 and 
PC-9/ER1, 2, 3, 4 and 5 cells. 
 
Supplemental Figure 3. Protein expression in PC-9 and PC-9/ER3, 4 and 5 cells 
treated with or without erlotinib for 6 hours. 
 
Supplemental Figure 4. Target protein expression in PC-9 and PC-9/ER3 cells treated 
with each indicated concentrations of LY294002 or static. 
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Supplemental Figure 5. Growth inhibition ratio after treatment with erlotinib plus 
JSI-124 of PC-9/ER5 cells. 
 
Supplemental Figure 6. The combination of erlotinib with inhibition of JAK2 using 
siRNA in PC-9/ER3 cells suppressed pAkt in PC-9/ER3 cells. 
 
Supplemental Figure 7. 
Inhibition of JAK2 suppresses c-MYC expression. 
 
Page 43 of 49
CAS Editorial office (Email: cancerscience@wiley.com)
Cancer Science
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review
  
 
 
Establishment of an erlotinib-resistant lung cancer cell line.  
A, Overview of the strategy to establish erlotinib-resistant cells from PC-9 cells. B, A light microscopic 
(×100) image of PC-9 and PC-9/ER3 cells. Cells were exposed to erlotinib (1 µM) for 72 hours. C, Relative 
cell numbers of PC-9 and PC-9/ER3 are shown in the culture medium for 72 hours. PC-9 and PC-9/ER3 cells 
were seeded on 6-cm dishes (4 × 10 5per dish) in the absence of erlotinib. Cells were trypsinized and 
counted in triplicate. DT, doubling time. Data are presented as the mean ± standard error. D, Cells (3 × 103 
per well) were seeded onto 96-well plates in quadruplicate and grown in the absence or presence of the 
indicated concentration of erlotinib. After 96 hours, the cells were subjected to MTT assays. PC-9/ER3 cells 
were maintained in culture medium without erlotinib for 5 (5W), 10 (10W), or 20 (20W) weeks.  
111x190mm (300 x 300 DPI)  
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Characterization of PC-9/ER3 cells.  
A, The T790M mutation was not found in PC-9/ER3 cells by direct sequencing. B, MET gene copy number 
was examined by quantitative PCR using genomic DNA extracted from PC-9 and PC-9/ER3 cells. MET gene 
copy number relative to GAPDH was measured in three independent experiments. Bars, standard deviation. 
C, Cells were incubated with or without 2 µM erlotinib for 6 hours and subjected to Western blotting. pEGFR 
was suppressed, and PTEN expression was similar in both cell lines.  
111x190mm (300 x 300 DPI)  
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Protein expression in PC-9 and PC-9/ER3 cells treated with erlotinib for various lengths of time.  
pEGFR and pMAPK in both cell lines were markedly suppressed. pAkt was not inhibited by erlotinib, and 
pJAK2 increased in PC-9/ER3 cells more than in the parental PC-9 cells. pSTAT3 increased in both PC-9 and 
PC-9/ER3 cells in a time-dependent manner. Although expression of survivin did not change during erlotinib 
treatment, PC-9/ER3 cells had more expressions than PC-9 cells as a base line.  
111x190mm (300 x 300 DPI)  
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Comparison of cell growth after treatment with drugs alone or in combination.  
A, Cells (3 × 103 per well) were seeded in 96-well plates in quadruplicate and grown in the absence or 
presence of the indicated concentration of JSI-124. After 96 hours, the cells were subjected to MTT assays. 
B, Cells (3 × 103 per well) were seeded in 96-well plates in quadruplicate and grown in the absence or 
presence of the indicated concentration of erlotinib with or without 0.05 µM JSI-124. After 96 hours, the 
cells were subjected to MTT assays. C and D, Same as in (A) and (B), respectively, but with LY294002. The 
concentration of LY290442 in (D) was 15 µM. E and F, Same as in (A) and (B), respectively, but with stattic. 
The concentration of stattic in (F) was 5 µM. G, Cells were treated with 10 nM erlotinib plus or minus 30 nM 
JSI-124 (left panel), 5 µM LY294002 (center panel), or 2 µM stattic (right panel) for 96 hours. Growth 
inhibition relative to erlotinib-untreated cells with or without JSI-124, LY294002, or stattic are shown. Data 
are representative of two independent experiments. Bars, standard error.  
111x190mm (300 x 300 DPI)  
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Protein expression in PC-9 and PC-9/ER3 cells upon treatment with erlotinib plus or minus JSI-124.  
Extracts from PC-9 and PC-9/ER3 cell lines, treated with erlotinib (0.01 µM) or JSI-124 (10 µM) or both for 6 
hours, were subjected to Western blotting. Treatment with erlotinib alone inhibited pMAPK in both cell lines 
and pAkt in PC-9, but not PC-9/ER3, cells. Treatment with JSI-124 alone inhibited pJAK2, pSTAT3, and 
pMAPK in both cell lines and pAkt in PC-9/ER3, but not in PC-9, cells. pAkt in PC-9 cells treated with both 
erlotinib and JSI-124 was similar to that with erlotinib alone. However, in PC-9/ER3 cells, JSI-124 
moderately suppressed pAkt. The combination of both drugs suppressed pAkt as much as that in PC-9 cells 
treated with erlotinib alone.  
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siRNA knockdown of STAT3 and JAK2.  
A, STAT3 was knocked down in PC-9 and PC-9/ER3 cells by STAT3-specific siRNA. B, Cells (3 × 103 per well) 
were seeded in 96-well plates in quadruplicate and grown with the indicated concentration of erlotinib. After 
96 hours, the cells were subjected to MTT assays. The knockdown of STAT3 did not affect the sensitivity to 
erlotinib of either cell line. C, JAK2-specific siRNA lowered JAK2 expression. D, The knockdown of JAK2 did 
not influence the sensitivity of PC-9 cells to erlotinib, but restored the sensitivity of PC-9/ER3 cells to 
erlotinib.  
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Growth curves of PC-9/ER3 xenograft tumors.  
PC-9/ER3 xenograft model mice were treated with JSI-124 (1 mg/kg/day) alone, erlotinib (25 mg/kg/day) 
alone, erlotinib in combination with JSI-124, or vehicle alone. JSI-124 alone did not inhibit tumor growth. 
Erlotinib alone did not significantly affect the tumor volume. The two-drug combination resulted in significant 
tumor shrinkage compared to either drug alone (P < 0.05). Differences in tumor volume were compared 
using Student's t-test. Bars, standard error.  
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Supplemental Fig. 1 
All the resistant cells were significantly resistant to erlotinib and gefitinib. 
Supplemental Fig. 2 
MET gene copy number was examined by quantitative PCR using 
genomic DNA in three independent experiments. Bars, standard 
deviation. 
MET gene copy number relative to GAPDH in PC-9 and PC-9/ER1, 
2, 3, 4 and 5 cells.  
Supplemental Fig. 3 
Protein expression in PC-9 and PC-9/ER3, 4 and 5 cells treated 
with or without erlotinib for 6 hours. 
Supplemental Fig. 4 
A 
B 
Target protein expression in PC-9 and PC-9/ER3 cells treated with 
each indicated concentrations of LY294002 or static. 
pAkt was inhibited by LY294002 in cells incubated for 6 hours in a 
dose-dependent manner.  
pSTAT3 was inhibited by stattic in cells incubated for 12 hours in a 
dose-dependent manner. 
Supplemental Fig. 5 
Growth inhibition ratio after treatment with erlotinib plus JSI-124 
of PC-9/ER5 cells. 
Cells were treated with 10 nM erlotinib plus or minus 30 nM JSI-
124 for 96 hours. Growth inhibition relative to erlotinib-untreated 
cells with or without JSI-124 was shown. Data are representative of 
three independent experiments. Bars, standard error. 
Supplemental Fig. 6 
The combination of erlotinib with inhibition of JAK2 using siRNA 
in PC-9/ER3 cells suppressed pAkt in PC-9/ER3 cells. 
Supplemental Fig. 7 
Inhibition of JAK2 suppresses c-MYC expression. 
Extracts from PC-9 and PC-9/ER3 cell lines, which were treated 
with erlotinib (0.01 μM) or JSI-124 (1 μM), or both, for 12 hours, 
were subjected to Western blotting. The combination of erlotinib 
and JSI-124 efficiently suppressed c-MYC expression in the PC-
9/ER3 cells. 
Western blotting shows that siRNA knockdown of JAK2 
inhibited c-MYC protein expression in PC-9 and PC-9/ER3 cells.  
